Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine

Head and Neck Oncology

Volumn 2, Issue 1, 2010, Pages

  Sharon, Elad ^a   Kelly, Ronan J ^a   Szabo, Eva ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE; TRASTUZUMAB; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BONE BIOPSY; BONE METASTASIS; CANCER STAGING; CARCINOMA EX PLEOMORPHIC ADENOMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MALE; PAROTIDECTOMY; PLEOMORPHIC ADENOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SALIVARY GLAND TUMOR; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; TUMOR REGRESSION; TUMOR VOLUME; BIOSYNTHESIS; ENZYMOLOGY; MIDDLE AGED;

ADENOMA, PLEOMORPHIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; SALIVARY GLAND NEOPLASMS;

EID: 77953952160     PISSN: None     EISSN: 17583284     Source Type: Journal    
DOI: 10.1186/1758-3284-2-12     Document Type: Article

References (11)

1. Systemic therapy in the palliative management of advanced salivary gland cancers. SA Laurie L Licitra, J Clin Oncol 2006 24 2673 2678 10.1200/JCO.2005.05.3025 16763282
2. Carcinoma ex pleomorphic adenoma: a clinicopathologic review. KD Olsen JE Lewis, Head Neck 2001 23 705 712 10.1002/hed.1100 11505478
3. Carcinoma of the parotid and submandibular glands - a study of survival in 2465 patients. P Wahlberg H Anderson A Biorklund T Moller R Perfekt, Oral Oncol 2002 38 706 713 10.1016/S1368-8375(02)00007-6 12167424
4. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. SG Surakanti M Agulnik, Semin Oncol 2008 35 309 319 10.1053/j.seminoncol.2008.03.009 18544445
5. Phase II study of capecitabine plus trastuzumab in human epidermal growht factor receptor 2-overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. G Schaller I Fuchs T Gonsch J Weber A Kleine-Tebbe,, et al. J Clin Onc 2007 25 3246 3250 10.1200/JCO.2006.09.6826 (Pubitemid 47325608)
6. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. S Sugano K Mukai H Tsuda,, et al. Laryngoscope 1992 102 923 927 10.1288/00005537-199208000- 00013 1353853
7. Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. JE Lewis KD Olsen TJ Sebo, Hum Pathol 2001 32 596 604 10.1053/hupa.2001.25000 11431714
8. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. R Haddad AD Colevas JF Krane,, et al. Oral Oncol 2003 39 724 727 10.1016/S1368-8375(03)00097-6 12907212
9. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. M Agulnik EW Cohen RB Cohen,, et al. J Clin Oncol 2007 25 3978 3984 10.1200/JCO.2007.11.8612 17761983
10. Biological therapy of salivary duct carcinoma. M Nashed RJ Casasola, J Laryngol Otol 2009 123 250 252 10.1017/S0022215108002314 18405406
11. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. A Prat M Parera V Reyes S Peralta,, et al. Head & Neck 2008 30 680 683 10.1002/hed.20714 17972317